According to scientists, clinical trials for the Israeli COVID-19 drug , which is inhaled and did not cause side effects during the first phase of the clinical trials in patients, have started in Greece. The COVID-19 drug will be used in a clinical study undertaken by the research team of Sotiris Tsiodras, a professor of Infectious Diseases. Specifically, Nadir Arber, Professor of Medicine at the Tel Aviv Medical Center and head of the Cancer Prevention Center, is in Greece and will have meetings with Prime Minister Kyriakos Mitsotakis at the Maximos Palace, in the presence of Sotiris Tsiodras. It is noted that yesterday, Professor Nadir Arber was received at Attikon Hospital by the Deputy Minister of Health Vassilis Kontozamanis and Professor Sotiris Tsiodras. Professor Nadir Arber. Kontozamanis welcomed Professor Arber to Greece, emphasising that with his scientific research he laid the foundations for the creation of an innovative drug. "We are optimistic that it will contribute effectively to the fight against the pandemic," he said. The Deputy Minister of Health immediately added that the clinical study for the new drug will start in Greece, in collaboration with Israeli scientists. It is recalled that during his recent visit to Israel, Prime Minister Kyriakos Mitsotakis discussed and agreed with his Israeli counterpart, Benjamin Netanyahu, the participation of Greek hospitals in clinical trials. Mitsotakis and Netanyahu. This COVID-19 treatment is an inhaled drug that at the first indications has achieved promising results with efficacy rates of 96% in the patients tested: Specifically, 29 out of 30 were discharged from the hospital within three to five days after received the treatment. More specifically, according to the Times of Israel, the discovery concerns the substance EXO-CD24, which was developed by scientists at the Ichilov Medical Center in Tel Aviv. The drug, which is the result of research by Professor Arber, was originally designed to treat ovarian cancer. He said that "even if the vaccines do their job, even if there are no new mutations, one way or another the coronavirus will stay with us," added that "this is why we developed this special medicine". READ MORE: Greek doctors contact Israeli counterparts about new COVID-19 drug.